AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| AIM | AIM ImmunoTech Inc. | 2026-04-02 18:42:53 | 0.57 | -0.02 | -4.02 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AIM | 0000946644 | AIM ImmunoTech Inc. | US00901B3033 | — | 520845822 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 2117 SW HIGHWAY 484 | OCALA | FL | 32801 | UNITED STATES | US | 352-448-7797 | 2117 SW HIGHWAY 484, OCALA, FL, 32801 | 2117 SW HIGHWAY 484, OCALA, FL, 32801 | AIM ImmunoTech Inc. | Biopharmaceutical | — | — | — | — | 6,411,460 | 3,069,875 | 8,147,782 | AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees. | 2026-04-02 20:53:25 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 6,411,460 | -14,381,894 | -69.1658 | 8,147,782 | -64,142,248 | -88.729 |
| 2024 | 20,793,354 | -11,036,128 | -34.6727 | 72,290,030 | 22,388,853 | 44.8664 |
| 2023 | 31,829,482 | -4,425,001 | -12.2054 | 49,901,177 | 1,493,851 | 3.086 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Thomas K | President, CEO | 2024 | 783,333 | 0 | 200,000 | 0 | 106,392 | 1,089,725 |
| Robert Dickey | CFO | 2024 | 49,549 | 0 | 0 | 0 | 0 | 49,549 |
| Thomas K | President, CEO | 2023 | 850,000 | 350,000 | 0 | 0 | 103,189 | 1,431,301 |
| Robert Dickey | CFO | 2023 | 54,484 | 10,000 | 0 | 0 | 0 | 64,484 |
| Ellen Lintal | CFO | 2020 | 239,583 | 177,000 | 0 | 0 | 25,403 | 553,602 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 88,000 | 170,000 | 202,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 3,924,000 | 6,197,000 | 10,939,000 |
| General And Administrative Expenses | 7,700,000 | 13,714,000 | 21,137,000 |
| Operating Expenses | 11,752,000 | 19,942,000 | 32,118,000 |
| Operating Income | -11,664,000 | -19,772,000 | -31,916,000 |
| Net Income | -13,958,000 | -17,320,000 | -28,962,000 |
| Earnings Per Share Basic | -8.62 | -0.31 | -0.6 |
| Earnings Per Share Diluted | -8.62 | -0.31 | -0.6 |
| Weighted Average Shares Outstanding Basic | 1,618,617 | 56,016,870 | 48,270,000 |
| Weighted Average Shares Outstanding Diluted | 1,618,617 | 56,016,870 | 48,585,404 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 2,985,000 | 1,701,000 | 5,439,000 |
| Marketable Securities Current | 62,000 | 2,276,000 | 7,631,000 |
| Accounts Receivable | 7,000 | — | 1,184,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 3,295,000 | 4,176,000 | 14,556,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 71,000 | 108,000 | 127,000 |
| Other Assets Non Current | 377,000 | 1,112,000 | 1,688,000 |
| Total Assets Non Current | 2,487,000 | 4,432,000 | 4,825,000 |
| Total Assets | 5,782,000 | 8,608,000 | 19,381,000 |
| Accounts Payable | 1,630,000 | 6,383,000 | 6,443,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 3,549,000 | 2,307,000 | — |
| Other Liabilities Current | 795,000 | 606,000 | 1,986,000 |
| Total Liabilities Current | 6,224,000 | 9,535,000 | 8,652,000 |
| Long Term Debt | 4,476,000 | 2,807,000 | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 9,341,000 | 395,000 | 495,000 |
| Total Liabilities | 15,565,000 | 9,930,000 | 9,147,000 |
| Common Stock | 3,000 | 66,000 | 49,000 |
| Retained Earnings | -440,786,000 | -426,828,000 | -409,508,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | -9,783,000 | -1,322,000 | 10,234,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 37,000 | 302,000 | 39,000 |
| Share Based Compensation Expense | 60,000 | 686,000 | 243,000 |
| Other Non Cash Income Expense | -294,000 | — | 18,000 |
| Change In Accounts Receivable | — | -1,184,000 | -492,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | 7,000 | — | — |
| Change In Other Assets | -735,000 | -576,000 | 486,000 |
| Change In Accounts Payable | -1,712,000 | -60,000 | 6,066,000 |
| Change In Other Liabilities | 416,000 | -1,198,000 | 1,180,000 |
| Cash From Operating Activities | -10,957,000 | -14,888,000 | -21,267,000 |
| Purchases Of Marketable Securities | 91,000 | 361,000 | 1,593,000 |
| Sales Of Marketable Securities | — | 663,000 | — |
| Acquisition Of Property Plant And Equipment | — | 18,000 | — |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | 1,853,000 | 4,706,000 | -832,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 485,202 | 131,000 | 150,500 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 10,388,000 | 6,444,000 | 485,000 |
| Change In Cash | 1,284,000 | -3,738,000 | -21,614,000 |
| Cash At End Of Period | 2,985,000 | 1,701,000 | 5,439,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 247,000 | 585,000 | — |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -8.62 | -0.31 | -0.6 |
| Price To Earnings Ratio | -0.131 | -63.8071 | -73.2435 |
| Earnings Growth Rate | 2,680.6452 | -48.3333 | 50 |
| Price Earnings To Growth Ratio | -0.0 | 1.3201 | -1.4649 |
| Book Value Per Share | -6.044 | -0.0236 | 0.212 |
| Price To Book Ratio | -0.1868 | -838.1429 | 207.2775 |
| Ebitda | -13,109,000 | -16,433,000 | -28,923,000 |
| Enterprise Value | 6,867,256.7313 | 1,111,437,891.974 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.8203 | -3.8684 | — |
| Capital Expenditures | 0 | 283,000 | -29,000 |
| Free Cash Flow | -10,957,000 | -15,171,000 | -21,238,000 |
| Return On Equity | 1.4268 | 13.1014 | -2.83 |
| One Year Beta | 0.6445 | 0.7696 | 1.4436 |
| Three Year Beta | 0.8559 | 0.8451 | 0.8477 |
| Five Year Beta | 0.7781 | -0.3408 | -0.3395 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| CHEMEROW DAVID I. | Director | 2026-03-12 | 25,000 | A | 28,441 |
| CHEMEROW DAVID I. | Director | 2026-03-12 | 25 | D | 0 |
| Equels Thomas K | Director, CEO & President | 2026-03-12 | 25,000 | A | 63,922 |
| Equels Thomas K | Director, CEO & President | 2026-03-12 | 25 | D | 0 |
| CHEMEROW DAVID I. | Director | 2026-02-05 | 2,800 | A | 3,441 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | 2025-12-31 | 32 | 28 | 1.1429 |
| OSAIC HOLDINGS, INC. | 2025-12-31 | 16 | 15 | 1.0667 |
| Tower Research Capital LLC (TRC) | 2025-12-31 | 141 | 125 | 1.128 |
| MORGAN STANLEY | 2025-12-31 | 976 | 864 | 1.1296 |
| DRW Securities, LLC | 2025-12-31 | 78,585 | 69,545 | 1.13 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| AMERICAN CENTURY ETF TRUST | 2025-11-30 | Avantis International Equity ETF | AVDE | 5,405 | 10,713.69 | 0.0001 |
| AMERICAN CENTURY ETF TRUST | 2025-11-30 | Avantis Responsible International Equity ETF | AVSD | 1,822 | 3,611.54 | 0.0009 |
| FIDELITY CONCORD STREET TRUST | 2025-11-30 | Fidelity Series Total Market Index Fund | FCFMX | 682 | 1,036.64 | 0.0 |
| FIDELITY CONCORD STREET TRUST | 2025-11-30 | Fidelity Extended Market Index Fund | FSMAX | 15,458 | 23,496.16 | 0.0001 |
| AMERICAN CENTURY ETF TRUST | 2025-08-31 | Avantis Responsible International Equity ETF | AVSD | 1,040 | 2,347.54 | 0.0011 |